SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert® MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US2673) compared to diagnostic algorithms using only sputum microscopy and culture (US2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US39992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.
SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert® MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US2673) compared to diagnostic algorithms using only sputum microscopy and culture (US2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US39992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.
Authors: D Rimland; T R Navin; J L Lennox; J A Jernigan; J Kaplan; D Erdman; C J Morrison; S P Wahlquist Journal: AIDS Date: 2002-01-04 Impact factor: 4.177
Authors: D Lieberman; F Schlaeffer; I Boldur; D Lieberman; S Horowitz; M G Friedman; M Leiononen; O Horovitz; E Manor; A Porath Journal: Thorax Date: 1996-02 Impact factor: 9.139
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12
Authors: Christopher K Lippincott; Melissa B Miller; Elena B Popowitch; Colleen F Hanrahan; Annelies Van Rie Journal: Clin Infect Dis Date: 2014-04-11 Impact factor: 9.079
Authors: J Lucian Davis; L Masae Kawamura; Lelia H Chaisson; Jennifer Grinsdale; Jihane Benhammou; Christine Ho; Anna Babst; Houmpheng Banouvong; John Z Metcalfe; Mark Pandori; Philip C Hopewell; Adithya Cattamanchi Journal: Am J Respir Crit Care Med Date: 2014-06-15 Impact factor: 21.405